午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

ChemicalBook--->CAS DataBase List--->1207113-88-9

1207113-88-9

1207113-88-9 Structure

1207113-88-9 Structure
IdentificationBack Directory
[Name]

CCG-100602
[CAS]

1207113-88-9
[Synonyms]

CCG-100602
CCG-100602 >=98% (HPLC)
1-[3,5-bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)piperidine-3-carboxamide
3-Piperidinecarboxamide, 1-[3,5-bis(trifluoromethyl)benzoyl]-N-(4-chlorophenyl)-
[Molecular Formula]

C21H17ClF6N2O2
[MOL File]

1207113-88-9.mol
[Molecular Weight]

478.82
Chemical PropertiesBack Directory
[storage temp. ]

-20°C
[solubility ]

≤0.2mg/ml in ethanol;20mg/ml in DMSO;20mg/ml in dimethyl formamide
[form ]

powder
[color ]

white to beige
Hazard InformationBack Directory
[Uses]

The Rho family of small GTPases play an important role in transduction of cell signaling events associated with several human cancers. CCG-1423 is a specific inhibitor of Rho pathway-mediated signaling and activation of serum response factor (SRF) transcription. The site of inhibition in the pathway is not precisely defined but CCG-1423 appears to act on some aspect of the interaction of SRF with its transcriptional cofactor megakaryoblastic leukemia 1 (MKL1) at a point upstream of DNA binding. CCG-100602 is a CCG-1423 analog developed for improved selectivity, potency, and attenuated cytotoxicity relative to its parent compound. CCG-100602 inhibits RhoA/C-mediated, SRF-driven luciferase expression in PC-3 prostate cancer cells with an IC50 value of 9.8 μM. At 100 μM, CCG-100602 demonstrates 72% inhibition of PC-3 cell invasion into a Matrigel model of metastasis, exhibiting an efficacy:toxicity profile superior to that of CCG-1423 at 10 μM.[Cayman Chemical]
[Biological Activity]

ccg-100602 is a rho pathway inhibitor.rho, a member of the ras superfamily of small gtp-binding proteins, plays a key role in various biological processes including microtubule dynamics, gene transcription, actin cytoskeleton organization, cell cycle progression, oncogenic transformation, as well as epithelial wound repair.
[in vitro]

ccg-100602 was developed as a ccg-1423 analog for improved selectivity, potency, and attenuated cytotoxicity. it was found that ccg-100602 was able to inhibit rhoa/c-mediated and srf-driven luciferase expression in pc-3 prostate cancer cells. at 100 μm, ccg-100602 showed 72% inhibition of pc-3 cell invasion into a matrigel model of metastasis, having an superior efficacy-toxicity profile to that of ccg-1423 [1].
[in vivo]

to evaluate whether inhibition of srf could protect podocytes from hyperglycaemia injury, daily ip administration of ccg-1423 was performed in dm rata. results showed that ccg-1423 could ameliorate proteinuria dose-dependently. ccg-1423 at 0.02 mg/kg could significantly reduce the body weight, compared with the vehicle controls. in addition, the inhibition of srf with ccg-1423 also significantly abrogated the reduction of synaptopodin expression and the induction of srf,α-sma, fsp-1 expression in renal cortex tissues [2].
[IC 50]

9.8 μm for pc-3 prostate cancer cells
[storage]

4°C, protect from light
[References]

[1] evelyn, c. r.,bell, j.l.,ryu, j.g., et al. design, synthesis and prostate cancer cell-based studies of analogs of the rho/mkl1 transcriptional pathway inhibitor, ccg-1423. bioorganic & medicinal chemistry letters 20, 665-672 (2010).
[2] zhao l, wang x, sun l, nie h, liu x, chen z, guan g. critical role of serum response factor in podocyte epithelial-mesenchymal transition of diabetic nephropathy. diab vasc dis res. 2016 jan;13(1):81-92.
Spectrum DetailBack Directory
[Spectrum Detail]

CCG-100602(1207113-88-9)1HNMR
1207113-88-9 suppliers list
Company Name: TargetMol Chemicals Inc.
Tel: +1-781-999-5354 +1-00000000000 , +1-00000000000
Website: https://www.targetmol.com/
Company Name: InvivoChem
Tel: +1-708-310-1919 +1-13798911105 , +1-13798911105
Website: https://www.invivochem.com/
Company Name: Aladdin Scientific
Tel: +1-+1(833)-552-7181
Website: www.aladdinsci.com/
Company Name: Shanghai Lollane Biological Technology Co.,Ltd.  
Tel: 021-52996696,15000506266 15000506266
Website: http://www.bioll.com
Company Name: ShangHai Biochempartner Co.,Ltd  
Tel: 17754423994 17754423994
Website: https://www.biochempartner.com
Company Name: Shanghai SuperLan Chemcial Technique Centre  
Tel: 021-2022843681 15618226720
Website: http://www.yuhua99.com/ShowSupplierProductsList19886/0.htm
Company Name: DC Chemicals  
Tel: 021-58447131 13564518121
Website: http://www.yuhua99.com/ShowSupplierProductsList927327/0.htm
Company Name: ChemeGen(Shanghai) Biotechnology Co.,Ltd.  
Tel: 18818260767
Website: http://www.chemegen.com
Company Name: Energy Chemical  
Tel: 021-58432009 400-005-6266
Website: http://www.energy-chemical.com
Company Name: MedBioPharmaceutical Technology Inc  
Tel: 021-69568360 18916172912
Website: http://www.med-bio.cn/
Company Name: Jinan Jiuli Biotechnology Co. , Ltd.  
Tel: 15865264761
Website: www.yuhua99.com/showsupplierproductslist89365/0.htm
Company Name: Bide Pharmatech Ltd.  
Tel: 400-1647117 13681763483
Website: https://www.bidepharm.com/
Company Name: InvivoChem  
Tel: 13549236410
Website: https://www.invivochem.cn/
Company Name: TargetMol Chemicals Inc.  
Tel: 4008200310
Website: https://www.targetmol.cn/
Company Name: Shaoguan Qicheng Biotechnology Co., Ltd  
Tel: 18122215013
Website: http://www.yuhua99.com/ShowSupplierProductsList1488808/0.htm
Company Name:   
Tel:
Website: www.sangon.com
Company Name: ApexBio Technology  
Tel: + 1-832-696-8203
Website: www.apexbt.com
Company Name: Neobioscience Co., Ltd.  
Tel: 4006-800-892
Website: www.nbs-bio.com
Tags:1207113-88-9 Related Product Information

This site uses cookies
This website uses cookies and similar technologies to store and retrieve information about your use of this website. This information helps us to provide, analyse and improve our services, which may include personalised content or advertising. We may share this information with Google and other third parties. This cookies are necessary for our website to work properly . By clicking "Continue" or continuing to browse our site you are agreeing to our and our partners use of cookies.
Accept